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Introduction 
Atrial fibrillation is a well recognized 
risk factor of stroke.1 Various risk 
stratification models have been used but 
CHADS2 (an acronym for Congestive heart 
failure, Hypertension, Age over 75, Diabetes 
mellitus, and prior Stroke or transient 
ischemic attack) is the most commonly used 
model, possibly because of its easy scoring.2 
In this system, a point is given for 
congestive heart failure, hypertension, age 
over 75 years, and diabetes, and two points 
for previous history of stroke. CHADS2 
scoring places patients in one of three risk 
categories with a score of 0 as low, 1 as 
moderate, and more than or equal to 2 as 
high. Aspirin alone is recommended for low 
risk, aspirin or oral anticoagulants for 
moderate risk, and oral anticoagulants for 
high risk individuals.3 
Although anticoagulants are superior to 
aspirin alone or the combination of aspirin 
and clopidogril, they are associated with a 
significant risk of intracranial hemorrhage.4-
6
 The Atrial Fibrillation Clopidogrel Trial 
with Irbesartan for Prevention of Vascular 
Events (ACTIVE-W) analysis demonstrated 
the high efficacy of oral anticoagulation 
(OAC) over the combination of aspirin and 
clopidogril in patients with CHADS2 score 
of 1.7  Therefore, it is important to keep the 
balance between risks and benefits of 
starting warfarin in these patients. 
 
Case Report 
An 83-year-old male known to have 
hypertension, atrial fibrillation, hypo-
thyroidism, parkinsonism, bladder car-
cinoma (status post resection), diabetes 
mellitus type 2 on insulin, coronary artery 
disease (status post coronary artery bypass 
graph in two vessels) presented with 
generalized weakness, anorexia, and 
confusion for the past six months that 
worsened in the prior two weeks.  Review of 
the rest of systems was non-contributory.  
He had no allergies. He quit smoking and 
drinking several years prior.  
The patient’s father had diabetes 
mellitus; the rest of the family history was 
unremarkable.  He was taking warfarin 2 mg 
daily for chronic atrial fibrillation, insulin, 
levothyroxine, lisinopril, carvedilol, 
amlodipine, citalopram, levetiracetim, 
carbidopa/levadopa, and hydrocodone.  
On examination, blood pressure was 
139/83 mmHg and controlled with 
medication, heart rate was 75 bpm, 
respiratory rate was 20 bpm, and 
temperature was 98oF.  Positive physical 
findings were depressed mood, dry mucous 
membranes suggestive of mild dehydration, 
3/6 holosystolic murmur in the left lower 
sternal border, and chronic venous stasis 
changes noted in bilateral lower extremities. 
The electrocardiogram and chest x-ray were 
normal. 
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Blood work was normal except for 
hemoglobin at 11.4 g/dl and platelets at 96 x  
109/L. The patient was admitted for IV 
rehydration. His INR was 2.54 and the 
following day his brain natriuretic peptide 
came back 808 pg/mL, therefore careful 
diuresis with furosemide was started with 
strict intake and output charting.  
On the 5th post admission day, the 
patient was more confused and disoriented 
from his baseline mental status.  A plain 
computed tomography (CT) scan of the head 
revealed intraventricular hemorrhage 
(Figure 1). His INR that day was 3.5. 
Therefore, warfarin therapy was 
discontinued and fresh frozen plasma was 
given for the reversal of anticoagulation.  He 
was transferred to the neuro-intensive care 
unit and monitored closely for five days.  No 
improvement in his condition was observed 
and he was transferred to hospice care. He 
died a few days later. 
 
 
Figure 1. Intraventricular hemorrhage 
revealed on CT scan. 
 
Discussion 
The estimation of bleeding risk related to 
warfarin therapy is important. Risk is 
different  for  individual  patients.    To  help  
physicians in risk stratification, various 
bleeding risk models for patients on warfarin 
have been developed. An early outpatient 
bleeding risk index for warfarin-treated 
patients provided an evidence-based starting 
point for warfarin therapy rather than relying 
on the physician’s prediction.8  Four risk 
factors were identified, including age over 
65, history of stroke, history of 
gastrointestinal bleeds, and one of the 
following: diabetes mellitus, creatinine over 
1.5 mg/dL, hematocrit over 30%, or recent 
myocardial infarction. According to this 
model, patients were classified as low risk 
(no risk factor), intermediate risk (1-2 risk 
factors), and high risk (3-4 risk factors) for 
bleeding.  
Another model predicts the risk of 
bleeding for patients receiving warfarin.9  
This model considered age over 60, sex, and 
malignancy in their formula, (1.6 X age) + 
(1.3 X female sex) + (2.2 X malignancy), to 
calculate the score and subsequent 
stratification of the patients as high (more 
than 3 points), intermediate (1-3 points), or 
low risk (0 points). 
In 2006, Shireman and colleagues10 
proposed a new model to simplify the 
queries regarding risks of warfarin therapy.  
Eight factors including age over 70 years, 
gender, remote bleed, recent bleed, 
alcohol/drug abuse, diabetes, anemia, and 
anti-platelet therapy use are considered. 
Bleeding rates then are compared with rates 
derived using other models. 
All these models have clinical 
implications. Hypertension was not studied 
in any of these models.  Hypertension is the 
single most important risk factor for the 
intracerebral hemorrhage (ICH).11-13  It is 
one of the components of CHADS score and 
a very important risk factor for ICH. A 
revised   bleeding   risk   model   should    be 
designed to address hypertension as one of 
the risk factors for bleed in patients 
receiving warfarin. 
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Conclusion 
The risk of intracranial bleeding is 
associated with oral anticoagulation therapy 
with warfarin. Multiple risk factors have 
been associated with the risk of bleeding. 
Association between hypertension and 
intracranial bleeding is well established. 
Various bleeding risk models in patients on 
warfarin have been developed, but the 
relationship of high blood pressure with 
warfarin therapy and the risk of intracranial 
bleed has not been studied comprehensively. 
Further studies are needed to guide 
physicians and avoid grave complications 
like intracranial bleed. 
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